Efficacy of rituximab as third-line therapy in combined central and peripheral demyelination

Combined central and peripheral demyelination (CCPD) is a rare autoimmune demyelinating disorder affecting both CNS and peripheral nervous system (PNS). Prevalence is probably underestimated, since in relapsing-remitting multiple sclerosis (MS)–like forms the PNS involvement is frequently undetected. The pathogenesis is largely unknown, prognosis is poor, and treatment options, including steroids and IV immunoglobulins (IVIg), are limited and almost ineffective.1–3

Source: Neurology Clinical Practice - December 11, 2017 Category: Neurology Authors: Savasta, S., Foiadelli, T., Vegezzi, E., Cortese, A., Lozza, A., Pichiecchio, A., Franciotta, D., Marchioni, E. Tags: All Clinical Neurology, Chronic inflammatory demyelinating polyneuropathy, All Demyelinating disease (CNS) Case Source Type: research